Tim Lugo


William Blair Maintains Outperform On Salix Following Cosmo Deal Cancellation

In a research report issued today, William Blair analyst Tim Lugo maintained an Outperform rating on Salix Pharmaceuticals (NASDAQ:SLXP) with a $184 price target, following today’s …

William Blair Comments On Endo Following Proposal To Acquire Auxilium

In a research report issued today, William Blair analyst Tim Lugo assigned a Market Perform rating on Endo Health Solutions (NASDAQ:ENDP) with a …

We Continue To Believe That Shares Of Agile Hold A Strong Risk/Reward Profile, Says William Blair

In a research report released today, William Blair analyst Tim Lugo reaffirmed an Outperform rating on Agile Therapeutics (NASDAQ:AGRX) with an $18 price …

BioDelivery Sciences Remains A Top Pick Within Our Coverage, Says William Blair

In a research report published yesterday, William Blair analyst Tim Lugo maintained an Outperform rating on BioDelivery Sciences (NASDAQ:BDSI) with a $25 price …

William Blair Reaffirms Outperform On Zogenix, But Reduces PT To $3 Given Reduced Zohydro Expectations

On Friday, August 1, Zogenix (ZGNX) announced the departure of Chief Commercial Officer Scott Shively at the same time Express Scripts (ESRX) decided to …

William Blair Reaffirms Outperform On Allergan Following Solid 2Q14 Results

In a research report released yesterday, William Blair analyst Tim Lugo reaffirmed an Outperform rating on Allergan Inc. (AGN), following the release of the …

William Blair Maintaines Outperform On Salix Following Positive FDA Guidance For Relistor Appeal

In a research report issued yesterday, William Blair analyst Tim Lugo maintained an Outperform rating on Salix Pharmaceuticals (SLXP) with a $157 price target, following a …

Salix Holds One Of The Highest Organic Growth Potential In Its Industry, Says William Blair

In a research report released yesterday, William Blair analyst Tim Lugo maintained an Outperform rating on Salix Pharmaceuticals Ltd. (SLXP) with a $157 …

William Blair Maintains Market Perform On Shire In Light Of AbbVie’s Recent Acquisition Offer

In a research note reported yesterday, William Blair analyst Tim Lugo maintained a Market Perform rating on Shire PLC. (SHPG) with a $250.

William Blair Maintains Outperform On BioDelivery Following Positive Phase III Results

In a research report published Monday, William Blair analyst Tim Lugo maintained an Outperform rating on BioDelivery Sciences International Inc. (BDSI) and raised …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts